Scancell founder says the company is ready to commercialise novel medicines to counteract cancer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTate & Lyle Regulatory News (TATE)

Share Price Information for Tate & Lyle (TATE)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 675.50
Bid: 675.00
Ask: 676.00
Change: 2.00 (0.30%)
Spread: 1.00 (0.148%)
Open: 674.00
High: 678.50
Low: 672.50
Prev. Close: 673.50
TATE Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Statement

30 Sep 2010 07:00

null

30 September 2010 - Tate & Lyle PLC

Trading Update

Tate & Lyle issues the following trading update for the six months ending 30 September 2010 ahead of the announcement of the Half Year Results on Thursday 4 November 2010.

Javed Ahmed, Chief Executive, said: "The encouraging start to the year has continued in the second quarter, particularly within Speciality Food Ingredients, with good operational performance and solid demand in a number of our markets. This underpins our confidence that we will make progress in the full financial year."

OPERATING PERFORMANCE - CONTINUING OPERATIONS

In Speciality Food Ingredients, growth in speciality sweeteners and starches remained steady. Sucralose volume growth was robust albeit, as expected, at lower average selling prices. Our single plant Sucralose manufacturing base continues to deliver substantial cost efficiencies.

Within Bulk Ingredients, corn sweetener volumes benefited from a continuation of the firm demand patterns for HFCS in Mexico and good demand over the summer in both the US and Europe. Industrial starch volumes in both the Americas and Europe were ahead of the prior year, although margins continued to be weak. Ethanol margins improved slightly in the second quarter, although the market remained under pressure.

CORN PRICES

Corn prices across the US and Europe have risen through the summer. In the US, where we fully hedge the gross cost of corn for use in each sales contract, higher associated co-product prices delivered a benefit in the quarter. In Europe, where hedging options are more limited, while we benefited from higher co-product prices during the first half of the year, higher corn prices are expected to have a modest impact on profitability on current contracts during the final quarter of the 2010 calendar year.

SUGARS - DISCONTINUED OPERATIONS

We are completing today on the sale of our EU Sugar Refining operations for a cash consideration of £211 million after initial working capital adjustments. The proceeds are subject to working capital finalisation and completion on the related sales of two small minority shareholdings in Italy and Laos. The disposal processes of the remaining businesses within our Sugars division, principally Molasses and Vietnamese Sugar, are progressing well.

DEBT MANAGEMENT

We expect to report further underlying net debt reduction in the second quarter despite anticipated higher grain inventories at the end of September as a result of the earlier harvest in the US. We paid £46 million in respect of the final dividend for the year ended 31 March 2010 in July.

Reported net debt will reduce further following today's receipt of the proceeds from the disposal of our EU Sugar Refining operations.

OUTLOOK

In Speciality Food Ingredients, we expect a continuation of the growth patterns experienced during the first half of the year.

In Bulk Ingredients, we expect the firm demand for corn sweeteners into Mexico to continue alongside the modest ongoing decline in US domestic demand, subject to normal seasonal patterns, and stable demand in our other food markets. As usual, the outcome of the 2011 calendar year sweetener pricing rounds will influence performance in the final quarter of the financial year. Despite some improvement in demand, the industrial starch markets remain under pressure.

The encouraging first half performance underpins our confidence that we will make progress in the full financial year.

END

Notes to Editor:

1. A conference call will be held today at 8.00am BST, hosted by Javed Ahmed, Chief Executive and Tim Lodge, Chief Financial Officer. Participants are requested to dial in at least 5 minutes before the commencement of the call. Dial in details are as follows:

Participant dial in number: +44 (0) 1452 555 566 (UK freephone 0800 694 0257)Conference ID: 12985616Replay dial in number: +44 (0) 1452 55 00 00 (UK freephone 0800 953 1533)Replay passcode: 12985616#

A replay of this call will be available from two hours after the end of the live call for 7 days until 6 October 2010.

2. We have published today on our website www.tateandlyle.com Group income statements for the six months ending 30 September 2009 and for the year ending 31 March 2010 reflecting the reclassification of the Sugars division within discontinued operations.

For more information contact Tate & Lyle PLC:

Chris McLeish, Group VP, Investor and Media RelationsTel: +44 (0) 20 7977 6211 or Mobile: +44 (0) 7919 102 730

William Baldwin-Charles, Head of Media RelationsTel: +44 (0) 20 7977 6165 or Mobile: +44 (0) 7810 151 425

About Tate & Lyle:

Tate & Lyle is a global provider of ingredients and solutions to the food, beverage and other industries, operating from more than 45 production facilities around the world. Through our large-scale, efficient manufacturing plants, we turn raw materials into distinctive, high quality ingredients for our customers. Our ingredients and solutions add taste, texture, nutrition and increased functionality to products that millions of people around the world use or consume every day.

Tate & Lyle's range of leading branded food ingredients includes SPLENDA® Sucralose, PROMITOR™ Dietary Fiber and STA-LITE® Polydextrose. Tate & Lyle also produces branded industrial ingredients including Bio-PDO™, Ethylex® and Sta-Lok® paper starches; and staple ingredients such as high fructose corn syrup, ethanol, citric acid and basic starches. In addition to providing a wide range of ingredients our Innovation and Commercial Development Group supports customers by providing product development, technical advice and proprietary consumer insight studies.

Tate & Lyle is listed on the London Stock Exchange under the symbol TATE.L. American Depositary Receipts trade under TATYY. In the year to 31 March 2010, Tate & Lyle employed 5,666 people in its subsidiaries and joint ventures, and sales totalled £3.6 billion. http://www.tateandlyle.com.

SPLENDA® is a trademark of McNeil Nutritionals, LLC

Copyright Business Wire 2010

Date   Source Headline
4th Jun 20245:22 pmRNSAnnual Financial Report and Notice of AGM
4th Jun 202411:00 amRNSDirector/PDMR Shareholding
3rd Jun 202412:00 pmRNSTotal Voting Rights
30th May 202412:15 pmRNSHolding(s) in Company
23rd May 20247:00 amRNSFinal Results
23rd May 20247:00 amRNSSale of remaining interest in Primient JV to KPS
20th May 20241:00 pmRNSDirectorate Change
17th May 20243:30 pmRNSHolding(s) in Company
14th May 20243:30 pmRNSHolding(s) in Company
13th May 202410:00 amRNSHolding(s) in Company
8th May 20243:15 pmRNSHolding(s) in Company
1st May 20242:30 pmRNSTotal Voting Rights
25th Apr 20243:45 pmRNSHolding(s) in Company
24th Apr 20247:00 amRNSDirectorate Change
22nd Apr 20242:30 pmRNSDirector/PDMR Shareholding
19th Apr 202410:15 amRNSHolding(s) in Company
17th Apr 20244:15 pmRNSHolding(s) in Company
17th Apr 202410:30 amRNSHolding(s) in Company
15th Apr 202410:30 amRNSHolding(s) in Company
10th Apr 20243:45 pmRNSHolding(s) in Company
8th Apr 202411:15 amRNSHolding(s) in Company
5th Apr 20243:45 pmRNSHolding(s) in Company
4th Apr 20244:15 pmRNSHolding(s) in Company
4th Apr 202412:30 pmRNSHolding(s) in Company
4th Apr 202411:30 amRNSDirector/PDMR Shareholding
2nd Apr 202412:45 pmRNSTotal Voting Rights
2nd Apr 202411:30 amRNSHolding(s) in Company
28th Mar 202411:45 amRNSHolding(s) in Company
25th Mar 202411:45 amRNSHolding(s) in Company
21st Mar 20244:10 pmRNSHolding(s) in Company
20th Mar 20243:00 pmRNSHolding(s) in Company
20th Mar 202412:00 pmRNSHolding(s) in Company
19th Mar 20242:00 pmRNSHolding(s) in Company
13th Mar 20244:00 pmRNSHolding(s) in Company
12th Mar 20244:24 pmRNSHolding(s) in Company
12th Mar 20244:22 pmRNSHolding(s) in Company
7th Mar 20247:00 amRNSDirectorate Change
4th Mar 20242:00 pmRNSDirector/PDMR Shareholding
4th Mar 20241:45 pmRNSHolding(s) in Company
28th Feb 20242:30 pmRNSHolding(s) in Company
21st Feb 20247:00 amRNSTrading Statement
1st Feb 202412:00 pmRNSTotal Voting Rights
11th Jan 20241:00 pmRNSDirector/PDMR Shareholding
2nd Jan 202412:00 pmRNSBlock listing Interim Review
8th Dec 202311:45 amRNSDirector/PDMR Shareholding
6th Dec 202310:30 amRNSHolding(s) in Company
27th Nov 20234:15 pmRNSHolding(s) in Company
23rd Nov 20232:30 pmRNSHolding(s) in Company
20th Nov 202310:00 amRNSHolding(s) in Company
9th Nov 20237:00 amRNSHalf-year Report

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.